|
KMID : 1200020190430050590
|
|
Diabetes & Metabolism Journal
2019 Volume.43 No. 5 p.590 ~ p.606
|
|
|
Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Korean Patients with Type 2 Diabetes Mellitus in Real-World Clinical Practice
|
|
Hong A-Ram
Koo Bo-Kyung
Kim Sang-Wan
Yi Ka-Hee
Moon Min-Kyong
|
|
|
Abstract
|
|
|
Background: This study aimed to evaluate the efficacy and safety of sodium-glucose cotransporter-2 (SGLT2) inhibitors in Korean patients who had inadequately controlled type 2 diabetes mellitus (T2DM) in real-world clinical practice.
Methods: We included 410 patients who started SGLT2 inhibitors (empagliflozin or dapagliflozin) as add-on therapy or switch therapy between February 2015 and June 2017. The primary efficacy endpoint was a change in glycosylated hemoglobin (HbA1c) from baseline to week 12. The secondary endpoints were patients achieving HbA1c <7.0% and changes in the fasting plasma glucose (FPG), lipid profiles, body weight, and blood pressure (BP).
Results: The mean HbA1c at baseline was 8.5% (8.6% in the add-on group and 8.4% in the switch group). At week 12, the mean adjusted HbA1c decreased by ?0.68% in the overall patients (P<0.001), by ?0.94% in the add-on group, and by ?0.42% in the switch group. Significant reductions in FPG were also observed both in the add-on group and switch group (?30.3 and ?19.8 mg/dL, respectively). Serum triglyceride (?16.5 mg/dL), body weight (?2.1 kg), systolic BP (?4.7 mm Hg), and diastolic BP (?1.3 mm Hg) were significantly improved in the overall patients. Approximately 18.3% of the patients achieved HbA1c <7.0% at week 12. A low incidence of hypoglycemia and genital tract infection was observed (6.3% and 2.2%, respectively).
Conclusion: SGLT2 inhibitors can be a suitable option as either add-on or switch therapy for Korean patients with inadequately controlled T2DM.
|
|
|
KEYWORD
|
|
|
Blood glucose, Diabetes mellitus, type 2, Hypoglycemia, Sodium-glucose transporter 2
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
   
|
|